Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Chronic myeloid leukaemia, chronic phase, drawn from the whole corpus: 11 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The leukaemic stem cells that survive kinase inhibition and cause relapse after stopping.
Nothing recorded yet.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Cardiovascular toxicity over decades on second- and third-generation inhibitors.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Access to any tyrosine kinase inhibitor, and to PCR monitoring, in low-income countries.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 12 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
Newly diagnosed Ph+ CML chronic phase
A milestone in how this cancer is treated.
Newly diagnosed Ph+ CML chronic phase